At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 832 enrolled
Drug / intervention
Intravenous thrombolysis plus tirofiban +1 moredrug
Likely dose
Intravenous thrombolysis plus tirofiban 0.4 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)
The First Affiliated Hospital of University of Science and Technology of China·interventional·Posted Nov 18, 2023·Updated May 4, 2025
In Brief
A Phase 3 clinical trial evaluating Intravenous thrombolysis plus tirofiban and Intravenous thrombolysis plus placebo for Acute Ischemic Stroke. Completed, enrolled 832 participants across 1 site.
Detailed Summary
To assess the efficacy and safety of tirofiban administration after intravenous thrombolysis for patients with AIS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedNov 2023
Enrollment StartMar 2024
Primary CompletionSep 2024
Study CompletionDec 2024
TodayJul 2026
First PostedNov 18, 2023
Enrollment StartMar 14, 2024
Primary CompletionSep 25, 2024
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.6 years ago
Interventions
Intravenous thrombolysis plus tirofibandrug
Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
Intravenous thrombolysis plus placebodrug
placebo (saline)